Previous Article | Next Article ![]()
Clinical and Vaccine Immunology, August 2008, p. 1282-1291, Vol. 15, No. 8
1071-412X/08/$08.00+0 doi:10.1128/CVI.00044-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Centro de Investigação em Saúde da Manhiça (CISM), Manhiça, Mozambique,1 Instituto Nacional de Saude,2 Direcção Nacional de Saúde, Ministerio da Saúde, Maputo, Mozambique,3 Barcelona Centre for International Health Research (CRESIB), Hospital Clínic/IDIBAPS, Universitat de Barcelona, Barcelona, Spain,4 International Centre for Genetic Engineering and Biotechnology, New Delhi, India5
Received 30 January 2008/ Returned for modification 17 March 2008/ Accepted 15 May 2008
We evaluated the impact of intermittent preventive treatment in infants (IPTi) with sulfadoxine-pyrimethamine (SP), which was given at ages 3, 4, and 9 months through the Expanded Program on Immunization (EPI), on the development of antibody responses to Plasmodium falciparum in Mozambique. Immunoglobulin M (IgM) and IgG subclass antibodies specific to whole asexual parasites and to recombinant MSP-119, AMA-1, and EBA-175 were measured at ages 5, 9, 12, and 24 months for 302 children by immunofluorescence antibody tests and by enzyme-linked immunosorbent assays. Antibody responses did not significantly differ between children receiving IPTi with SP and those receiving a placebo at any time point measured, with the exception of the responses of IgG and IgG1 to AMA-1 and/or MSP-119, which were significantly higher in the SP-treated group than in the placebo group at ages 5, 9, and/or 24 months. IPTi with SP given through the EPI reduces the frequency of malarial illness while allowing the development of naturally acquired antibody responses to P. falciparum antigens.
Published ahead of print on 21 May 2008.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»